Diagnostic value of abnormal chromosome 3p genes in small‑cell lung cancer

Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Ma,Chunxu; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Zhao,Jihua; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wu,Ying; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Jun; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao; Wang,Hao

doi:10.3892/ol.2022.13330

Diagnostic value of abnormal chromosome 3p genes in small‑cell lung cancer

Authors:
- Chunxu Ma
- Jihua Zhao
- Ying Wu
- Jun Wang
- Hao Wang
View Affiliations

Affiliations: Department of Nuclear Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, College of Physical Education, Yunnan Agricultural University, Kunming, Yunnan 650201, P.R. China
Published online on: May 16, 2022 https://doi.org/10.3892/ol.2022.13330
Article Number: 209
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The diagnosis of small cell lung carcinoma (SCLC) remains a great challenge. Changes in chromosome 3p (chr3) genes are usually observed in the pathogenesis of lung cancer, which suggests that these chr3 genes may be a diagnostic marker in the early stage of SCLC. The present study explored the diagnostic value of the chr3 gene in SCLC using Bioinformatics. Furthermore, reverse transcription‑quantitative PCR (RT‑qPCR) was used to reveal the expression patterns of diagnostic biomarkers in human pulmonary alveolar epithelial cells and in the SCLC cell line NCI‑H146. A total of 33 differentially expressed (DE) chr3 genes and 1,156 module genes associated with clinical features of patients with SCLC were identified and functional enrichment analysis indicated that all these genes were significantly enriched in cell cycle terms. The area under the receiver operating characteristic curve demonstrated that the overlapping genes of the DE‑chr3 and module genes, namely cell division cycle 25 A (CDC25A), FYVE and coiled‑coil domain autophagy adaptor 1 (FYCO1) and lipid raft linker 1 (RFTN1), were relatively accurate in distinguishing normal from SCLC samples, and may thus be considered diagnostic biomarkers. CDC25A was overexpressed in SCLC samples, while FYCO1 and RFTN1 were highly expressed in normal samples, as evidenced by the RT‑qPCR results. Single‑gene gene set enrichment analysis suggested that the diagnostic biomarkers were significantly associated with cell cycle, ATP‑binding cassette transporter, immune cell differentiation, immune response and multiple respiratory disease pathways. Furthermore, a total of 141 drugs were predicted by The Comparative Toxicogenomics Database to be able to modulate the expression of the diagnostic biomarkers, of which 8 drugs were shared among the three aforementioned diagnostic biomarkers. The present study identified three novel and powerful diagnostic biomarkers for SCLC based on chr3 genes. Suggestions for the development and selection of drugs for clinical treatment based on diagnostic biomarkers were also provided.

View Figures

View References

1	Semenova EA, Nagel R and Berns A: Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 29:1447–1462. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Rudin CM, Brambilla E, Faivre-Finn C and Sage J: Small-cell lung cancer. Nat Rev Dis Primers. 7:32021. View Article : Google Scholar : PubMed/NCBI
4	Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R; Staging and Prognostic Factors Committee, ; et al: The international association for the study of lung cancer lung cancer staging project: Proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 11:300–311. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A, Berezovski MV and Kichkailo AS: Current and prospective protein biomarkers of lung cancer. Cancers (Basel). 9:1552017. View Article : Google Scholar : PubMed/NCBI
6	Liu L, Teng J, Zhang L, Cong P, Yao Y, Sun G, Liu Z, Yu T and Liu M: The combination of the tumor markers suggests the histological diagnosis of lung cancer. Biomed Res Int. 2017:20139892017.PubMed/NCBI
7	Li YL, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, et al: Patterns of somatic structural variation in human cancer genomes. Nature. 578:112–121. 2020. View Article : Google Scholar : PubMed/NCBI
8	Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI
9	Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature. 450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
10	Petursdottir TE, Thorsteinsdottir U, Jonasson JG, Moller PH, Huiping C, Bjornsson J, Egilsson V, Imreh S and Ingvarsson S: Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues. Genes Chromosomes Cancer. 41:232–242. 2004. View Article : Google Scholar : PubMed/NCBI
11	Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
12	The Gene Ontology Consortium, . Expansion of the gene ontology knowledgebase and resources. Nucleic Acids Res. 45:D331–D338. 2017. View Article : Google Scholar : PubMed/NCBI
13	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
14	Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, et al: The reactome pathway knowledgebase. Nucleic Acids Res. 46:D649–D655. 2018. View Article : Google Scholar : PubMed/NCBI
15	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
16	Sandeep A, Praveen VK, Kartha KK, Karunakaran V and Ajayaghosh A: Supercoiled fibres of self-sorted donor-acceptor stacks: A turn-off/turn-on platform for sensing volatile aromatic compounds. Chem Sci. 7:4460–4467. 2016. View Article : Google Scholar : PubMed/NCBI
17	Li W, Zhang H, Assaraf YG, Zhao K, Xu XJ, Xie JB, Yang DH and Chen ZS: Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 27:14–29. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chauncey TR: Drug resistance mechanisms in acute leukemia. Curr Opin Oncol. 13:21–26. 2001. View Article : Google Scholar : PubMed/NCBI
19	Pérez-Tomás R: Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
20	Zhu MR, Huang Y, Bender ME, Girard L, Kollipara R, Eglenen-Polat B, Naito Y, Savage TK, Huffman KE, Koyama S, et al: Evasion of innate immunity contributes to small cell lung cancer progression and metastasis. Cancer Res. 81:1813–1826. 2021. View Article : Google Scholar : PubMed/NCBI
21	Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC and Mattingly CJ: Comparative toxicogenomics database (CTD): Update 2021. Nucleic Acids Res. 49:D1138–D1143. 2021. View Article : Google Scholar : PubMed/NCBI
22	Liao Y, Yin GF, Wang X, Zhong P, Fan XM and Huang CL: Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis. Oncol Lett. 18:3723–3733. 2019.PubMed/NCBI
23	Shen T and Huang S: The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 12:631–639. 2012. View Article : Google Scholar : PubMed/NCBI
24	Sadeghi H, Golalipour M, Yamchi A, Farazmandfar T and Shahbazi M: CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation. J Cell Biochem. 120:2919–2928. 2019. View Article : Google Scholar : PubMed/NCBI
25	Ray D, Terao Y, Fuhrken PG, Ma ZQ, DeMayo FJ, Christov K, Heerema NA, Franks R, Tsai SY, Papoutsakis ET and Kiyokawa H: Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 67:984–991. 2007. View Article : Google Scholar : PubMed/NCBI
26	Sengupta S, Jana S and Bhattacharyya A: TGF-β-Smad2 dependent activation of CDC 25A plays an important role in cell proliferation through NFAT activation in metastatic breast cancer cells. Cell Signal. 26:240–252. 2014. View Article : Google Scholar : PubMed/NCBI
27	Brunetto E, Ferrara AM, Rampoldi F, Talarico A, Cin ED, Grassini G, Spagnuolo L, Sassi I, Ferro A, Cuorvo LV, et al: CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: Implication for a potential clinical relevance in trastuzumab treatment. Neoplasia. 15:579–590. 2013. View Article : Google Scholar : PubMed/NCBI
28	Albert H, Santos S, Battaglia E, Brito M, Monteiro C and Bagrel D: Differential expression of CDC25 phosphatases splice variants in human breast cancer cells. Clin Chem Lab Med. 49:1707–1714. 2011. View Article : Google Scholar : PubMed/NCBI
29	Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, Lazo JS, Wang Z, Zhang L and Yu J: microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 69:8157–8165. 2009. View Article : Google Scholar : PubMed/NCBI
30	Butz H, Németh K, Czenke D, Likó I, Czirják S, Zivkovic V, Baghy K, Korbonits M, Kovalszky I, Igaz P, et al: Systematic investigation of expression of G2/M transition genes reveals CDC25 alteration in nonfunctioning pituitary adenomas. Pathol Oncol Res. 23:633–641. 2017. View Article : Google Scholar : PubMed/NCBI
31	Rao PC, Begum S, Sahai M and Sriram DS: Coptisine-induced cell cycle arrest at G2/M phase and reactive oxygen species-dependent mitochondria-mediated apoptosis in non-small-cell lung cancer A549 cells. Tumour Biol. 39:10104283176945652017. View Article : Google Scholar : PubMed/NCBI
32	Olsvik HL, Lamark T, Takagi K, Larsen KB, Evjen G, Øvervatn A, Mizushima T and Johansen T: FYCO1 contains a C-terminally extended, LC3A/B-preferring LC3-interacting Region (LIR) motif required for efficient maturation of autophagosomes during basal autophagy. J Biol Chem. 290:29361–29374. 2015. View Article : Google Scholar : PubMed/NCBI
33	Dionne LK, Peterman E, Schiel J, Gibieža P, Skeberdis VA, Jimeno A, Wang XJ and Prekeris R: FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation. J Cell Sci. 130:4051–4062. 2017. View Article : Google Scholar : PubMed/NCBI
34	Sillars-Hardebol AH, Carvalho B, de Wit M, Postma C, Delis-van Diemen PM, Mongera S, Ylstra B, van de Wiel MA, Meijer GA and Fijneman RJ: Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol. 31:89–96. 2010. View Article : Google Scholar : PubMed/NCBI
35	Eissa S, Matboli M, Awad N and Kotb Y: Identification and validation of a novel autophagy gene expression signature for human bladder cancer patients. Tumor Biology. Apr 5–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
36	Wang J, Qu D, An J, Yuan G and Liu Y: Integrated microarray analysis provided novel insights to the pathogenesis of glaucoma. Mol Med Rep. 16:8735–8746. 2017. View Article : Google Scholar : PubMed/NCBI
37	Li M, Chen Y, Yao J, Lu S, Guan Y, Xu Y, Liu Q, Sun S, Mi Q, Mei J, et al: Genome-wide association study of smoking behavior traits in a Chinese Han population. Front Psychiatry. 11:5642392020. View Article : Google Scholar : PubMed/NCBI
38	Zhao Y, Gao Y, Xu X, Zhou J and Wang H: Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma. BMC Cancer. 21:2572021. View Article : Google Scholar : PubMed/NCBI
39	Slatore CG, Au DH, Littman AJ, Satia JA and White E: Association of nonsteroidal anti-inflammatory drugs with lung cancer: Results from a large cohort study. Cancer Epidemiol Biomarkers Prev. 18:1203–1207. 2009. View Article : Google Scholar : PubMed/NCBI
40	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
41	Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
42	Kim JE, Lee SY, Jang M, Choi HK, Kim JH, Chen H, Lim TG, Dong Z and Lee KW: Coumestrol epigenetically suppresses cancer cell proliferation: Coumestrol is a natural haspin kinase inhibitor. Int J Mol Sci. 18:22282017. View Article : Google Scholar : PubMed/NCBI
43	Que Z, Zhou Z, Luo B, Dong C, Jiang Y, Li H and Tian J: Jingfukang induces anti-cancer activity through oxidative stress-mediated DNA damage in circulating human lung cancer cells. BMC Complement Altern Med. 19:2042019. View Article : Google Scholar : PubMed/NCBI
44	Platta CS, Greenblatt DY, Kunnimalaiyaan M and Chen H: Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res. 148:31–37. 2008. View Article : Google Scholar : PubMed/NCBI
45	Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P and Willems L: Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models. ERJ Open Res. 1:00028–2015. 2015. View Article : Google Scholar : PubMed/NCBI